MedPath

The influence of paclitaxel in drug-drug interaction via hepatic organic anion transporter

Not Applicable
Conditions
on-small cell lung cancer
Registration Number
JPRN-UMIN000032370
Lead Sponsor
Showa University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
10
Inclusion Criteria

Not provided

Exclusion Criteria

1) Severe complication (e.g., uncontrollable diabetis mellitus, liver disease) 2) Serological positive for HBs-antigen or HCV-antibody 3) Active synchronous cancer 4) Severe psychiatric disorder 5) Pregnant or lactating women, or men and women without wanting pregnancy 6) Severe hypersensitivity to medicine 7) Patients who were judged inappropriate for the study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Plasma concentrations of endogenous substrates for OATP before and after paclitaxel administration
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath